Medios AG (ILM1) Stock Price & Analysis
ILM1 Stock Chart & Stats
- Day’s Range
- CHF 9.62 - CHF 9.80
- 52-Week Range
- CHF 9.35 - CHF 11.83
- Previous Close
- CHF 9.92
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- CHF 249.12M
- Enterprise Value
- CHF 412.89M
- Total Cash (Recent Filing)
- CHF 83.16M
- Total Debt (Recent Filing)
- CHF 200.02M
- Price to Earnings (P/E)
- 24.0
- Beta
- 1.55
- Next Earnings
- Nov 10, 2026 (Est.)
- EPS Estimate
- 0.24
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth
The exceptional top-line expansion indicates strong demand for specialty-pharmaceutical distribution and patient-specific therapy services. Sustained growth can improve scale, deepen pharmacy relationships, and create operating leverage if profitability improves.
Positive Free Cash Flow
Positive free cash flow and reasonable conversion to earnings provide internal funding for operations and investment. This reduces reliance on external financing and supports resilience, although the recent decline in cash generation remains a constraint.
Manageable Balance Sheet Leverage
The substantial equity base and moderate debt-to-equity ratio provide financial capacity to support specialty-pharma operations. This balance-sheet foundation can help the company absorb volatility and fund growth without excessive dependence on new borrowing.
Bears Say
Very Thin Profitability
Thin margins leave limited protection against supplier costs, pricing pressure, operating expenses, or unfavorable product mix. Even substantial revenue growth may therefore produce only modest earnings, constraining reinvestment and increasing earnings sensitivity.
Weakening Cash Generation
The sharp reduction in free cash flow signals weaker cash conversion despite positive absolute cash generation. If this persists, internally funded expansion may become harder and the company could need more working-capital financing or debt.
Rising Debt And Modest Returns
Although current leverage is manageable, the upward debt trajectory increases financial risk if earnings weaken. The low return on equity also indicates limited profitability from invested capital, potentially reducing the efficiency of future balance-sheet expansion.
Medios AG News
ILM1 FAQ
What was Medios AG’s price range in the past 12 months?
What is Medios AG’s market cap?
When is Medios AG’s upcoming earnings report date?
How were Medios AG’s earnings last quarter?
Is Medios AG overvalued?
Does Medios AG pay dividends?
What is Medios AG’s EPS estimate?
How many shares outstanding does Medios AG have?
What happened to Medios AG’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Medios AG?
What is the TipRanks Smart Score and how is it calculated?
Medios AG Stock Smart Score
Company Description
Medios AG
Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through three segments: Patient-Specific Therapies; International Business; and Pharmaceutical Supply. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies. This segment also includes cytostatic preparations, antibody therapies, and parenteral nutrition solutions. The International Business International covers all activities in the international environment from the procurement of Active Pharmaceutical Ingredients, the sterile and non-sterile drugs and the supply of public and hospital pharmacies through homecare service. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases. Medios AG is founded in 2015 and was headquartered in Berlin, Germany.
- Sector
- Healthcare
- Industry
- Medical - Distribution
- CEO
- Thomas Meier
- Employees
- 989
- Website
- medios.group
- Address
- Heidestrasse 9, Berlin, BE, 10557, DE
Medios AG (ILM1) Earnings & Revenues
ILM1 Company Deck
ILM1 Earnings Call
Earnings Call SentimentPositive
The earnings call reflects a positive sentiment with strong financial performance and strategic advancements, despite some challenges in specific segments and increased costs related to acquisitions.
View all CH:ILM1 earnings summariesILM1 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 6 | 5 |
| Technical Analysis | 3 | 6 | 1 |
| Moving Averages | 4 | 0 | 4 |






